Collegium Pharmaceutical 对比 Corcept Therapeutics
可添加、更换或移除公司，最多四家。
简而言之
- Collegium Pharmaceutical 规模更大:2025 财年营收 $781M，Corcept Therapeutics 为 $761M。
- Collegium Pharmaceutical 营收增长更快(23.6%，对方为 12.8%)。
- Collegium Pharmaceutical 每一美元销售额中留下的营业利润更多(营业利润率 23.0%，对方为 5.9%)。
- Collegium Pharmaceutical 将更多销售额转化为自由现金流(自由现金流利润率 42.0%，对方为 18.6%)。
- Collegium Pharmaceutical 的投入资本回报更高(53.4%，对方为 15.7%)。
| 最近财年 | COLL · FY25 | CORT · FY25 |
|---|---|---|
| 规模 | ||
| 市值 | $746M | $10.2B |
| 营收 | $781M | $761M |
| 自由现金流 | $328M | $142M |
| 净利润 | $62.9M | $99.7M |
| 增长 | ||
| 营收增长 | 23.6% | 12.8% |
| 5年增长率 | 20.3% | 16.6% |
| 股数变化 | −1.8% | 5.7% |
| 盈利能力 | ||
| 毛利率 | 59.4% | 98.3% |
| 营业利润率 | 23.0% | 5.9% |
| 净利率 | 8.1% | 13.1% |
| 自由现金流利润率 | 42.0% | 18.6% |
| 资本回报率 | 53.4% | 15.7% |
| 股本回报率 | 23.7% | 15.0% |
| 资产负债表 | ||
| 净债务 | −$149M | −$372M |
| 净债务 / EBITDA | −0.4x | −8.1x |
| 股息与回购 | $25.1M | $173M |
| 估值与质量 | ||
| 市盈率 | 18.5x | — |
| Piotroski F 分数 | 6 | 3 |
FY16
COLL $1.7M
CORT $81.3M
FY17
COLL $28.5M
CORT $159M
FY18
COLL $280M
CORT $251M
FY19
COLL $297M
CORT $307M
FY20
COLL $310M
CORT $354M
FY21
COLL $277M
CORT $366M
FY22
COLL $464M
CORT $402M
FY23
COLL $567M
CORT $482M
FY24
COLL $631M
CORT $675M
FY25
COLL $781M
CORT $761M
COLL
CORT
FY16
COLL −5,498.7%
CORT 12.5%
FY17
COLL −265.0%
CORT 33.2%
FY18
COLL −7.4%
CORT 35.6%
FY19
COLL −8.0%
CORT 36.4%
FY20
COLL 18.1%
CORT 36.2%
FY21
COLL 6.4%
CORT 34.0%
FY22
COLL 7.2%
CORT 28.0%
FY23
COLL 29.5%
CORT 22.2%
FY24
COLL 26.9%
CORT 20.3%
FY25
COLL 23.0%
CORT 5.9%
COLL
CORT
FY16
COLL −$75.5M
CORT $18.2M
FY17
COLL −$68.0M
CORT $60.5M
FY18
COLL $164M
CORT $115M
FY19
COLL $21.3M
CORT $135M
FY20
COLL $88.4M
CORT $151M
FY21
COLL $102M
CORT $167M
FY22
COLL $123M
CORT $120M
FY23
COLL $274M
CORT $127M
FY24
COLL $203M
CORT $196M
FY25
COLL $328M
CORT $142M
COLL
CORT
FY16
COLL —
CORT —
FY17
COLL —
CORT 99.0%
FY18
COLL —
CORT 85.5%
FY19
COLL —
CORT 109.6%
FY20
COLL —
CORT 116.1%
FY21
COLL 10.4%
CORT 95.4%
FY22
COLL 16.5%
CORT 88.4%
FY23
COLL 68.7%
CORT 87.6%
FY24
COLL 53.0%
CORT 55.1%
FY25
COLL 53.4%
CORT 15.7%
COLL
CORT
各公司最近一个财年的数据；各公司财年结束月份不同。在越高(或越低)明显越好的行中，突出显示最佳值。不构成投资建议。